Fibrinogen in Liver Transplant
NCT07265843 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2025-12-05
Summary
The study is a prospective, multi-centered, unblinded, randomized controlled pilot study. The primary objective is to compare functional hemostatic capacity of two approved products Intercept Fibrinogen Complex (IFC) to Standard Cryoprecipitate Antihemophilic Factor (AHF) for liver transplant patients with bleeding and hypofibrinogenemia to determine impact of earlier access to a concentrated source of fibrinogen in a goal-directed manner.
Conditions
- Liver Transplant Surgery
Interventions
- BIOLOGICAL
-
Intercept Fibrinogen Complex (IFC)
INTERCEPT Fibrinogen Complex is a pathogen-reduced cryoprecipitated fibrinogen complex derived from human plasma. It contains fibrinogen, Factor XIII, and von Willebrand factor to achieve stable clot formation and restore hemostasis. Recently approved by the US Food and Drug Administration, it is used for the treatment of bleeding associated with fibrinogen deficiency.
- BIOLOGICAL
-
Cryoprecipitate Antihemophilic Factor (AHF)
Cryoprecipitate Antihemophilic Factor (AHF), also known as cryo, is a frozen blood product prepared from blood plasma. It is used for fibrinogen supplementation, particularly for hypofibrinogenemia fibrinogen, anemia associated with bleeding or congenital deficiency.
Sponsors & Collaborators
-
Trauma Hemostatis and Oxygenation Research (THOR) Network
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-01-01
- Primary Completion
- 2028-03-01
- Completion
- 2028-03-01
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease
NCT06014320 ·Status: UNKNOWN
-
Intraoperative Phlebotomies and Bleeding in Liver Transplantation
NCT04826666 ·Status: COMPLETED
-
Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation
NCT01563458 ·Status: COMPLETED ·Phase: PHASE2
-
Fibrinogen Concentrates Versus Cryoprecipitate in Liver Transplant Surgery
NCT06144112 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
The Efficacy of the Administration of Fibrinogen in Liver Transplantation
NCT01539057 ·Status: UNKNOWN ·Phase: PHASE3
-
Tranexamic Acid Versus Placebo for Blood to Reduce Perioperative Bleeding Post-liver Resection
NCT01651182 ·Status: COMPLETED ·Phase: PHASE3
-
Utilization of Donor Whole Blood for Blood Transfusion in Deceased Donor Liver Transplantation
NCT04383756 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Investigation of Systemic and Regional Haemostasis During Liver Transplantation by Comparing ClotPro® and TEG®
NCT04246307 ·Status: UNKNOWN
-
Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation
NCT02037373 ·Status: TERMINATED
-
Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Procedures
NCT00233246 ·Status: WITHDRAWN ·Phase: PHASE3
-
Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding
NCT05711524 ·Status: COMPLETED ·Phase: PHASE4
-
Rapid Diagnostic of Hyperfibrinolysis in Liver Transplantation
NCT03012633 ·Status: COMPLETED
-
Plasma Transfusion in Liver Transplantation
NCT00235183 ·Status: COMPLETED ·Phase: PHASE4
-
The Perioperative Value of Platelet Counts in Predicting Outcome After Liver Transplantation
NCT01711957 ·Status: UNKNOWN
-
Hepato-duodenal Ligament Occlusion and Classic Technique in Liver Transplant
NCT04265157 ·Status: UNKNOWN
-
Perioperative Hemostasis Management in Liver Transplantation
NCT06257407 ·Status: RECRUITING
-
Comparative Effectiveness of INTERCEPT Fibrinogen Complex (IFC) and Cryoprecipitate-AHF (Cryo-AHF) for Treatment of Trauma Associated Hemorrhage
NCT07218185 ·Status: NOT_YET_RECRUITING
-
The Effect of Tranexamic Acid on Blood Loss and Transfusion Requirements Following Open Femur Fracture Surgery
NCT03679481 ·Status: WITHDRAWN ·Phase: PHASE4
-
Noninferiority Oral Tranexamic Acid vs Intravenous Administration in Total Hip Arthroplasty
NCT04691362 ·Status: COMPLETED ·Phase: PHASE4
-
The Fibrin Pad Liver Study
NCT01166243 ·Status: COMPLETED ·Phase: PHASE3
-
.Patient Blood Management Program in Liver Transplantation
NCT05187637 ·Status: UNKNOWN
-
Tranexamic Acid Versus Placebo to Reduce Perioperative Bleeding After Major Hepatectomy
NCT00657384 ·Status: TERMINATED ·Phase: PHASE3
-
Platelet Count and Function After Usage of Two Different Cell Saver Devices During Liver Transplant Surgery
NCT06357455 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Major Abdominal Surgery
NCT00827931 ·Status: COMPLETED ·Phase: PHASE4
-
Von Willebrand Factor and Protein C Ratio in Graft Function After Liver Transplant
NCT04324255 ·Status: UNKNOWN